RT-PCR: A Preferred Method in Screening Infectious Diseases

High sensitivity and short turnaround time are favoring their growth over conventional PCR, culture and antigen-based assays, says RNCOS.

NOIDA, India (prHWY.com) August 6, 2012 - According to a new research report by RNCOS, the molecular diagnostics (MDx) segment is witnessing maximum growth within the global in-vitro diagnostics (IVD) industry. The overall MDx market is expected to grow at a significant CAGR of 10% during 2012-2015. The main factors driving the growth include new technology advancements and innovations that are resulting in faster & more accurate diagnosis and increasing awareness about these tests amongst the consumers.

Most laboratories performing MDx for infectious diseases prefer Real Time PCR (RT-PCR) based tests. Since, RT-PCR provides quantitative data about the virus, it is being increasingly sought to detect and judge the spread of virus infection in patient. Moreover, it is more sensitive and specific than traditional PCR based tests. It has a short turnaround time for results. All these factors have made RT-PCR an attractive replacement method for conventional PCR, culture and antigen-based assays, greatly influencing its sale and increasing its market share in the overall MDx market for infectious diseases. Significant players in this segment include, Roche, Abbot, Gen-Probe and Cepheid.

Moreover, the report by RNCOS titled, "Infectious Disease Molecular Diagnostics Outlook 2015", provides an effective insight and prudent analysis of the current status and future positioning of the global infectious diseases' MDx market. It projects the future size of overall market for the period 2012-2015 and covers effective description of key drivers and trends that will propel the growth.

Moreover, the report illustrates the current performance of key infectious disease diagnostic segments (in terms of indications) to enumerate vertical sector demand. It analyzes the opportunity assessment for companies in the market in terms of technologies (e.g. PCR, RT-PCR, NASBA etc.) and disease prevalence. Additionally, an in-depth insight into the FDA-approved diagnostics products along with recent industry developments has been included in the report to provide a balanced outlook on the potentials of the global infectious diseases MDx sector.

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM411.htm

Some of our Related Reports are:

- Global API Market Analysis (http://www.rncos.com/Report/IM320.htm)
- Global Telemedicine Market Analysis (http://www.rncos.com/Report/IM331.htm)
- Personalized Medicine Market Analysis (http://www.rncos.com/Report/IM305.htm)
- Global Regenerative Medicine Market (http://www.rncos.com/Report/IM363.htm)
- Emerging Pharmaceutical Markets Globally (http://www.rncos.com/Report/IM081.htm)

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm

About RNCOS

RNCOS specializes in Industry intelligence and creative solutions for contemporary business segments. Our professionals analyze the industry and its various components, with a comprehensive study of the changing market behavior. Our accuracy and data precision proves beneficial in terms of pricing and time management that assist the intending consultants in meeting their objectives in a cost-effective and timely manner.

###

Tag Words: molecular diagnostics

Categories: Health

Press Release Contact
B-129, Sector 6 Noida - 201301
91-120-4224-700
91-120-4224-707

Link To This Press Release:

URL HTML Code